Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sirtris muscles up

As many companies do, Sirtris Pharmaceuticals Inc. has been using a less than perfect compound to provide proof of principle for its foundational idea: that activating sirtuins will be useful for treating aging-related diseases. Last week, the company announced the discovery of structurally distinct and significantly more potent compounds.

The sirtuin class of histone deacetylase enzymes has been

Read the full 577 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers